<http://schema.org/description>
"The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox Chase Cancer Center researchers report that a combination of two molecularly-targeted agents may provide similar therapeutic benefit with less toxicity."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2011-06-toxic-combination-erlotinib-bevacizumab-effective.html>